Administrative Core

行政核心

• 批准号: 8375864
• 负责人: PHILIP Frederick SPARLING
• 金额: $ 68.35万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8375864
• 关键词: Academia; Alabama; Alphavirus; Animal Model; Antibodies; Antiviral Agents; Area; Bacillus anthracis spore; Bacteriology; Binding; Biology; Breathing; Categories; Chikungunya virus; Clinical; Clostridium; Collaborations; Commit; Communicable Diseases; Complement; Coronavirus; Dengue; Dengue Virus; Development; Disease; Drops; Emergency Situation; Emerging Communicable Diseases; Encephalitis Viruses; Environment; Epitopes; Extreme drug resistant tuberculosis; Flavivirus; Florida; Foundations; Francisella tularensis; Funding; Germination; Goals; Gram-Positive Bacteria; Health; Immune; Immune response; Immune system; Immunology; Immunosuppression; Individual; Infection; Infectious Agent; Institution; Intervention; Lead; Ligands; Lung; Mission; Modeling; Multidrug-Resistant Tuberculosis; Mutation; Natural Immunity; Nature; North Carolina; Pathogenesis; Pathway interactions; Pharmaceutical Preparations; Plague; Poxviridae; Prevention; Private Enterprises; Proteins; Public Health; Reagent; Reproduction spores; Research; Research Personnel; Research Training; Risk; Role; Route; Science; Scientist; Screening procedure; Structure; Sum; Testing; Translating; Tropism; Tularemia; Universities; Vaccines; Viral; Virulence; Virus; West Nile virus; Work; Zoonoses; base; biodefense; disorder risk; drug development; drug discovery; effective therapy; experience; human disease; influenzavirus; interest; member; mouse model; multidisciplinary; novel; novel vaccines; pathogen; pathogenic bacteria; programs; public-private partnership; receptor; response; structural biology; vaccine development; virology; virus pathogenesis

We are proud to present the SERCEB (Southeast Regional Center of Excellence for Emerging Infections and Biodefense) plan for the next five years of research, training and emergency response. Our organizing theme is "host-pathogen interactions: opportunities for intervention." We bring together an integrated and experienced team of superb investigators in virology, bacteriology, immunology, drug discovery and vaccine development whose ability to work together has been clearly demonstrated in the past five years. We believe our group is second to none, and look forward to the challenges and opportunities ahead with great confidence in our ability to deliver the highest quality discovery science, and in our ability to deliver clinically useful products. We work together in synergistic teams that span boundaries between universities, between basic scientists and public health workers,.and between academia and private enterprise. We are stronger by far than the sum of our individual parts. Our focus is in areas where our particular strengths add to or complement those of our partners throughout the national Regional Centers of Excellence (RCE) program. SERCEB is multidisciplinary team based in Region IV. The Prime Institution is the University of North Carolina Chapel Hill (UNC), and the other principal consortium members include Duke University, Emory University, Vanderbilt University, the University of Florida (Gainesville), and the University of Alabama at Birmingham. Our primary goal is to assist the nation in developing and deploying effective and rapid responses to biodefense and emerging infectious diseases threats. To this end, we will discover new therapies and principles by which effective new vaccines can be developed. Our pathways to discovery include better understanding of the pathogenic mechanisms by which pathogens cause disease and the nature of the immune responses against them. Hence, mechanistic studies on pathogenesis and animal models will also be a focus of study. We will concentrate on areas that offer promise for discovery of broad targets for therapy or prevention. We emphasize pathogen interactions with the innate immune system, an area of great SERCEB strength that offers excellent opportunities for discovery of broadly effective therapies. Discovery of new therapies also includes a focused screening and drug development team effort, which although not directly derived from studies of basic pathogenesis, depends in part on studies of pathogenesis to validate targets. Vaccine discovery is based on identification of crucial shared protective epitopes and protective, as opposed to deleterious, immune responses.

我们很自豪地推出 SERCEB（东南地区新发感染和疾病卓越中心） 生物防御）未来五年的研究、培训和应急响应计划。我们的组织主题 是“宿主-病原体相互作用：干预机会”。我们汇集了集成和 病毒学、细菌学、免疫学、药物发现和疫苗方面经验丰富的优秀研究人员团队 其共同努力的能力在过去五年中得到了明显的体现。我们相信 我们的团队是首屈一指的，充满信心地展望未来的挑战和机遇 我们有能力提供最高质量的发现科学，以及我们提供临床有用的能力 产品。我们在跨越大学之间、基础设施之间的协同团队中一起工作 科学家和公共卫生工作者，以及学术界和私营企业之间。到目前为止我们更强大 比我们各个部分的总和还要多。我们的重点是我们的特殊优势可以补充或补充的领域 我们的合作伙伴在整个国家区域卓越中心 (RCE) 计划中的表现。 SERCEB 是位于 IV 区的多学科团队。主要机构是北卡罗来纳大学 教堂山 (UNC) 和其他主要联盟成员包括杜克大学、埃默里大学、 范德比尔特大学、佛罗里达大学（盖恩斯维尔）和阿拉巴马大学伯明翰分校。我们的 主要目标是协助国家制定和部署有效、快速的应对措施 生物防御和新出现的传染病威胁。为此，我们将探索新的疗法和 开发有效新疫苗的原则。我们的发现途径包括更好的 了解病原体引起疾病的致病机制以及病原体的性质 针对它们的免疫反应。因此，发病机制和动物模型的机制研究将 也成为学习的重点。我们将专注于有希望发现广泛目标的领域 用于治疗或预防。我们强调病原体与先天免疫系统的相互作用，这是一个领域 SERCEB 的强大实力为发现广泛有效的疗法提供了绝佳的机会。 新疗法的发现还包括重点筛选和药物开发团队的努力，其中 虽然不是直接源自基本发病机制的研究，但部分取决于发病机制的研究 验证目标。疫苗的发现基于关键共享保护表位的识别和 保护性免疫反应，而不是有害的免疫反应。